Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$0.83 USD
+0.08 (11.08%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.84 +0.02 (1.82%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
MCRB 0.83 +0.08(11.08%)
Will MCRB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MCRB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MCRB
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
MCRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for MCRB
Biotech Alert: Searches spiking for these stocks today
Commit To Buy Seres Therapeutics At $0.50, Earn 27.3% Annualized Using Options
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Seres announces completion of patient enrollment for SERS-155 Phase 1b cohort 2
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences